Immutep (IMMP) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immutep Limited, a biotechnology company, has reported no change in revenue, a 50.7% increase in other income, and a larger net loss of $42.7 million for the fiscal year ended June 30, 2024, compared to the previous year. The increased loss is primarily due to higher R&D and clinical trial costs, despite a rise in interest income and a slight decrease in losses from changes in the fair value of convertible notes. No dividends were declared or paid during the period, and the net tangible asset backing per share increased to 12.5 cents.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.